

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 14

Complete if Known

Application Number	10/088,866
Filing Date	July 2, 2002
First Named Inventor	Ludger Dinkelborg et al.
Group Art Unit	1643
Examiner Name	Unknown
Attorney Docket Number	SCH-1869

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		
	A1	5,734,025		KOMAI et al.	03-1998
	A2	5,849,701		ROBERTS et al.	12-1998
	A3	5,747,452		RUOSLAHTI et al.	05-1998
	A4	5,837,813		RUOSLAHTI et al.	11-1998
	A5	5,523,229		FEINBERG et al.	06-1996
	A6	6,696,245		WINTER et al.	02-2004
	A7	5,710,134		BOSSLET et al.	01-1998
	A8	6,140,470		GAREN et al.	10-2000
	A9	5,648,485		DOLPHIN et al.	07-15-1997
	A10	5,817,776		GOODMAN et al.	10-06-1998
	A11	5,831,088		DOLPHIN et al.	11-03-1998
	A12	5,843,156		SLEPIAN et al.	12-01-1998
	A13	5,877,289		THORPE et al.	03-02-1999
	A14	5,913,884		TRAUNER et al.	06-22-1999
	A15	5,976,535		FRITZBERG et al.	11-02-1999
	A16	6,004,555		THORPE et al.	12-21-1999
	A17	6,015,897		THEODORE et al.	01-18-2000
	A18	6,036,955		THORPE et al.	03-14-2000
	A19	6,051,230		THORPE et al.	04-18-2000
	A20	6,093,399		THORPE et al.	07-25-2000
	A21	4,894,326		MATSUURA et al.	01-16-1990
	A22	6,749,853		THORPE et al.	06-15-2004
	A23	6,394,952		ANDERSON et al.	05-28-2002
	A24	6,267,722		ANDERSON et al.	07-31-2001
	A25	5,177,015		MATSUURA et al.	01-05-1993
	A26	2004/0013640		ZARDI et al.	01-22-2004

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Please type a plus sign (+) inside this box →

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/088,866
				Filing Date	July 2, 2002
				First Named Inventor	Ludger Dinkelborg et al.
				Group Art Unit	1643
				Examiner Name	Unknown
				Attorney Docket Number	SCH-1869
Sheet	2	of	14		

	A27	2004/0001790		HILGER et al.	01-01-2004
	A28	5,243,029		MATUSUURA et al.	09-07-1993
	A29	6,171,578		Dean et al.	01-2001
	A30	5,534,254		Huston et al.	07-1996
	A31	5,876,691		Chester et al.	03-1999
	A32	6,342,219		Thorpe et al.	01-2002
	A33	RE35,500		Rhodes, Buck A.	05-1997
	A34	7,273,924	B1	Neri et al.	09-2007
	A35	6,749,853		Thorpe et al.	06-2004
	A36	5,177,015		MATSUURA et al.	01-1993
	A37	5,837,813		Ruoslahti et al.	11-1998
	A38	7,273,924		Philogen S.p.A.	09-25-2007

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	B1	WO	9958570		Dario NERI et al.	10-18-1999		
	B2	WO	0162800		Dario NERI et al.	08-30-2001		
	B3	JP	0276598		SEKIGUCHI et al.	03-15-1990		√
	B4	JP	4169195		SEKIGUCHI et al.	06-17-1992		√
	B5	WO	9745544		Medical Res Council	12-04-1997		
	B6	WO	96/23816		CREIGHTON et al.	08-08-1996		
	B7	EP	184187		KUDO et al.	06-11-1986		
	B8	EP	239400		WINTER et al.	09-30-1987		
	B9	EP	0120694		BOSS et al.	10-03-1984		
	B10	WO	94/13804		HOLLIGER et al.	06-23-1994		
	B11	WO	93/11161		WHITLOW et al.	06-10-1993		
	B12	GB	2188638		NEUBERGER et al.	10-07-1987		
	B13	EP	0125023		CABILLY et al.	11-14-1984		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

+

+

+

+

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet	3	of	14
-------	---	----	----

Application Number	10/088,866
Filing Date	July 2, 2002
First Named Inventor	Ludger Dinkelborg et al.
Group Art Unit	1643
Examiner Name	Unknown
Attorney Docket Number	SCH-1869

++

+

+

+

+

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/088,866
				Filing Date	July 2, 2002
				First Named Inventor	Ludger Dinkelborg et al.
				Group Art Unit	1643
				Examiner Name	Unknown
Sheet	4	of	14	Attorney Docket Number	SCH-1869

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	TOMOHIKO FUKUDA ET AL., "Mice lacking the EDB segment of fibronectin develop normally but exhibit reduced cell growth and fibronectin matrix assembly in vitro," Cancer Research, 1 October 2002, pages 5603-5610, vol. 62.	
	C2	ANDREW GRIFFITHS ET AL., "Isolation of high affinity human antibodies directly from large synthetic repertoires," The EMBO Journal, 1994, pages 3245-3260, vol. 13, no. 14.	
	C3	Dario NERI et al., "Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform", Nature Biotechnology, Vol. 15, November 1997, pages 1271-1275	
	C4	Dario NERI et al., "Affinity reagents against tumour-associated extracellular molecules and newforming vessels," Advanced Drug Delivery Reviews, 6 April 1998, pages 43-52, vol. 31, no. 1-2, XP002124780, pages 46, right-hand column, page 49, left-hand column.	
	C5	PINI, A., et al., "Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel," Journal of Biological Chemistry, August 21, 1998, pages 21769-21776, Vol. 273, no. 34, XP002124781.	
	C6	VITI F. ET AL., "Increased Binding Affinity and Valence of Recombinant Antibody Fragments Lead to Improved Targeting of Tumoral Angiogenesis," Cancer Research, 15 January 1999, pp. 347-352, vol. 59, no. 2, XP002124782, the whole document.	
	C7	R. FATTORUSSO ET AL., "NMR structure of the human oncofetal fibronectin ED-B domain, a specific marker for angiogenesis", 15 April 1999, Structure, pp. 381-390, vol. 7, no. 4, XP002124783.	
	C8	TARLI L ET AL., "A high-affinity human antibody that targets tumoral blood vessels," Blood, 1 Jul 1999, pages 192-8, vol. 94, no. 1, XP002124784.	
	C9	M. ZALUTSKY ET AL., "Labeling monoclonal antibodies and F(ab')2 fragments with the alpha-particle-emitting nuclide astatine-211: preservation of immunoreactivity and in vivo localization," Proceedings of the National Academy of Sciences in the U.S.A., September 1989, vol. 86, no. 18, pages 7149-7153, XP002172060, Washington DC, USA, abstract.	
	C10	S. LINDEGREN ET AL., "Chloramine-T in high-specific-activity radioiodination of antibodies using N-succinimidyl-3-(trimehtylstannyl)benzoate as an intermediate," Nuclear Medicine and Biology, October 1998, pages 659-665, vol. 25, no. 7, XP004149436, Oxford, GB, abstract.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Please type a plus sign (+) inside this box →

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10/088,866
				Filing Date	July 2, 2002
				First Named Inventor	Ludger Dinkelborg et al.
				Group Art Unit	1643
				Examiner Name	Unknown
Sheet	5	of	14	Attorney Docket Number	SCH-1869

	C11	M. BIRCHLER ET AL., "Selective targeting and photocoagulation of ocular angiogenesis mediated by a phage-derived human antibody fragment," Nature Biotechnology, October 1999, pages 984-988, vol. 17, no. 10, XP002172061, New York, NY, USA, the whole document.	
	C12	Judah FOLKMAN, "Angiogenesis in cancer, vascular, rheumatoid and other disease", Nature Medicine, Vol. 1, Number 1, 1995, pages 27-31	
	C13	Renata PASQUALINI et al., "α-Vintegrins as receptors for tumor targeting by circulating ligands", Nature Biotechnology, Vol. 15, June 1997, pages 542-546.	
	C14	Michael S. O'REILLY et al., "Angiostatin induces and sustains dormancy of human primary tumors in mice", Nature Medicine, Vol. 12, Number 6, June 1996, pages 689-692	
	C15	Xianming HUANG et al., "Tumor Infarction in Mice by Antibody-Directed Targeting of Tissue Factor to Tumor Vasculature", Science, Vol. 275, January 24, 1997, pages 547-550	
	C16	Dario NERI et al., "Biophysical methods for the determination of antibody-antigen affinities", Tibtech (Vol. 14), December 1996, pages 465-470	
	C17	E. Sally WARD et al., "Binding activities of a repertoire of single immunoglobulin variable domains secreted from <i>Escherichia coli</i> ", Nature, Vol. 341, No. 6242, October 12, 1989, pages 544-546.	
	C18	James S. HUSTON, et al., "Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in <i>Escherichia coli</i> ", Proc. Natl. Acad. Sci. USA, Vol. 85, August 1988, pages 5879-5883	
	C19	Philipp HOLLIGER, et al., "'Diabodies': Small bivalent and bispecific antibody fragments", Proc. Natl. Acad. Sci. USA, Vol. 90, July 1993, pages 6444-6448	
	C20	Philipp HOLLIGER, et al., "Engineering bispecific antibodies", Current Opinion in Biotechnology, Vol. 4, No. 4, 1993, pages 446-449	
	C21	Cyrus CHOTHIA, et al., "Canonical Structures for the Hypervariable Regions of Immunoglobulins", Journal of Molecular Biology, Vol. 196, No. 4, August 20, 1987, pages 901-917	
	C22	D. NERI, et al., "Multipurpose High Sensitivity Luminescence Analyzer (LUANA): Use in Gel Electrophoresis", Biotechniques, Vol. 20, No. 4, April 1996, pages 708-712	
	C23	Ian M. TOMLINSON, et al., "The Repertoire of Human Germline V _H Sequence Reveals about Fifty Groups of V _H Segments with Different Hypervariable Loops", Academic Press, Vol. 227, No. 3, October 5, 1992, pages 776-798	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO <h2 style="text-align: center; margin: 10px 0;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center; margin-top: 10px;"><i>(use as many sheets as necessary)</i></p>		<div style="text-align: right; font-weight: bold; margin-bottom: 5px;">Complete if Known</div> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">Application Number</td> <td>10/088,866</td> </tr> <tr> <td>Filing Date</td> <td>July 2, 2002</td> </tr> <tr> <td>First Named Inventor</td> <td>Ludger Dinkelborg et al.</td> </tr> <tr> <td>Group Art Unit</td> <td>1643</td> </tr> <tr> <td>Examiner Name</td> <td>Unknown</td> </tr> <tr> <td>Attorney Docket Number</td> <td>SCH-1869</td> </tr> </table>		Application Number	10/088,866	Filing Date	July 2, 2002	First Named Inventor	Ludger Dinkelborg et al.	Group Art Unit	1643	Examiner Name	Unknown	Attorney Docket Number	SCH-1869
Application Number	10/088,866														
Filing Date	July 2, 2002														
First Named Inventor	Ludger Dinkelborg et al.														
Group Art Unit	1643														
Examiner Name	Unknown														
Attorney Docket Number	SCH-1869														
Sheet	6	of	14												

C24		Johnathan P. L. COX, et al., "A directory of human germ-line V _x segments reveals a strong bias in their usage", European Journal of Immunology 4/1994, pages 827-836	
C25		James D. MARKS, et al., "By-passing Immunization Human Antibodies from V-gene Libraries Displayed on Phage", Journal of Molecular Biology, Vol. 222, No. 3, December 5, 1991, pages 581-597	
C26		Hennie R. HOOGENBOOM, et al., "Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (FAB) heavy and light chains", Nucleic Acids Research, Vol. 19, No. 15, August 11, 1991, pages 4133-4137	
C27		Dario NERI, et al., "Radioactive labeling of recombinant antibody fragments by phosphorylation using human casein kinase II and [γ - ³² P]-ATP, Nature Biotechnology, Vol. 14, No. 4, April 1996, pages 485-490	
C28		Robert SCHIER, et al., "Identification of functional and structural amino-acid residues by parsimonious mutagenesis" Gene, Vol. 169, (1996), No. 2, pages 147-155	
C29		Wataru ITO, et al., "Mutations in the Complementarity-determining Regions do not cause Differences in Free Energy during the Process of Formation of the Activated Complex between an Antibody and the Corresponding Protein Antigen", Journal of Molecular Biology, Vol. 248, No. 4, May 12, 1995, pages 729-732	
C30		C. HAMERS-CASTERMAN, et al., "Naturally occurring antibodies devoid of light chains", International Weekly Journal of Science, Vol. 363, NO. 6428, June 3, 1993, pages 446-448	
C31		U. JÖNSSON, et al., "Real-Time Biospecific Interaction Analysis Using Surface Plasmon Resonance and a Sensor Chip Technology", Biotechniques, Vol. 11, No. 5, November 1991, pages 620-627	
C32		Ahuva NISSIM, et al., "Antibody fragments from a 'single pot' phage display library as immunochemical reagents", The Embo Journal, Vol. 13, No. 3, February 1, 1994, pages 692-698	
C33		Alessandro PINI, et al., "Hierarchical affinity maturation of a phage library derived antibody for the selective removal of cytomegalovirus from plasma", Journal of Immunological Methods, Vol. 206, nos-1-2, 1997, pages 171-182	
C34		Daniel R. DEEVER, "A new non-isotopic detection system for immunoassays", Nature, Vol. 377, No. 6551, October 26, 1995, pages 758-760	
C35		Matsuura H., Takio K., Titani K., Greene T., Levery SB, Salyan ME, Hakomori S., J. Biol. Chem. <u>263</u> , 3314-3322, "The oncofetal structure of human fibronectin defined by monoclonal antibody FDC-6. Unique structural requirement for the antigenic specificity provided by a glycosylhexapeptide", March 1988. Abstract Only	

Examiner Signature	Date Considered
--------------------	-----------------

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO <h2 style="text-align: center; margin: 10px 0;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center; margin-top: 10px;"><i>(use as many sheets as necessary)</i></p>		<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th colspan="2" style="text-align: center; font-weight: normal;">Complete if Known</th> </tr> <tr> <td style="width: 50%;">Application Number</td> <td>10/088,866</td> </tr> <tr> <td>Filing Date</td> <td>July 2, 2002</td> </tr> <tr> <td>First Named Inventor</td> <td>Ludger Dinkelborg et al.</td> </tr> <tr> <td>Group Art Unit</td> <td>1643</td> </tr> <tr> <td>Examiner Name</td> <td>Unknown</td> </tr> <tr> <td>Attorney Docket Number</td> <td>SCH-1869</td> </tr> </table>		Complete if Known		Application Number	10/088,866	Filing Date	July 2, 2002	First Named Inventor	Ludger Dinkelborg et al.	Group Art Unit	1643	Examiner Name	Unknown	Attorney Docket Number	SCH-1869
Complete if Known																	
Application Number	10/088,866																
Filing Date	July 2, 2002																
First Named Inventor	Ludger Dinkelborg et al.																
Group Art Unit	1643																
Examiner Name	Unknown																
Attorney Docket Number	SCH-1869																
Sheet	7	of	14														

C36		Zheng, M.ET AL., Int. J. Pept. Protein Res., 43 , 230-8, "Synthetic immunochemistry of glycohexapeptide analogues characteristic of oncofetal fibronectin. Solid-phase synthesis and antigenic activity"; March 1994. Abstract Only	
C37		Feinberg, RF, Kliman HJ, Bedian V, Monzon-Bordonaba F, Menzin AW, Wang CL; Am. J. Obstet. Gynecol 172 , 1526-1536; "Monoclonal antibody X18A4 identifies an oncofetal fibronectin epitope distinct from the FDC-6 binding site"; May 1995. Abstract Only	
C38		Paul K. Schick, Carol M. Wojenski, Vickie D. Bennett, and Tamara Ivanova; "The Synthesis and Localization of Alternatively Spliced Fibronectin EIIIB in Resting and Thrombin-Treated Megakaryocytes"; Blood, Vol. 87, No. 5, March 1, 1996; pp. 1817-1823	
C39		Denise G. White, James W. Hall, David W. Brandli, Amy L. Gehris, and Vickie D. Bennett; "Chick Cartilage Fibronectin Differs in Structure from the Fibronectin in Limb Mesenchyme"; 1996; Exp. Cell Res. 224, pp. 391-402	
C40		MARIANI ET AL., "Tumor Targeting Potential of the Monoclonal AntibodyvBC-1 against Oncofetal Fibronectin in Nude Mice Bearing Human Tumor Implants," The American Cancer Society, 15 December 1997, pp. 2378-2384, vol. 80, no. 12.	
C41		DARIO NERI ET AL., "Antibodies from phage display libraries as immunochemical reagents," Methods in Molecular Biology, Immunochemical protocols, 2 nd ed., pp. 475-500, vol. 80.	
C42		BIRCHLER ET AL., "Infrared photodetection for the in vivo localisation of phage-derived antibodies directed against angiogenic markers," Journal of Immunological Methods, 1999, pages 239-248, vol. 231.	
C43		FREDRIK NILSSON ET AL., "Targeted Delivery of Tissue Factor to the ED-B Domain of Fibronectin, a Marker of Angiogenesis, Mediates the Infarction of Solid Tumors in Mice," Cancer Research, 15 January 2001, pages 711-716, vol. 61.	
C44		HALIN ET AL., "Antibody-based targeting of Angiogenesis," Critical Reviews in Therapeutic Drug Carriers Systems, 2001, pages 299-339, vol. 28, no. 3.	
C45		LEONARDO GIOVANNONI ET AL., "Isolation of anti-angiogenesis antibodies from a large combinatorial repertoire by colony filter screening," Nucleic Acids Research, 2001, vol. 9, no. 5, e27.	
C46		SALVATORE DEMARTI ET AL., "Selective targeting of tumour neovasculature by a radiohalogenated human antibody fragment specific for the ED-B domain of fibronectin," European Journal of Nuclear Medicine, April 2001, short communication, vol. 28, no. 4.	
C47		BARBARA CARNEMOLLA ET AL., "Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix," Hemostasis, Thrombosis, and Vascular Biology, Blood, 1 March 2002, pages 1659-1665, vol. 99, no. 5.	
C48		HALIN ET AL., "Enhancement of the antitumor properties of interleukin-12 by its targeted delivery to the tumor blood vessel extracellular matrix," Nature Biotechnology, March 2002, pages 264-269, vol. 20.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO <h2 style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center;"><i>(use as many sheets as necessary)</i></p>		Complete if Known	
		Application Number	10/088,866
		Filing Date	July 2, 2002
		First Named Inventor	Ludger Dinkelborg et al.
		Group Art Unit	1643
		Examiner Name	Unknown
		Attorney Docket Number	SCH-1869

C49	C MARTY ET AL., "Cytotoxic targeting of F9 teratocarcinoma tumours with anti-ED-B fibronectin scFv antibody modified liposomes," British Journal of Cancer, 2002, pages 106-112, vol. 87, Cancer Research UK.	
C50	SAMU MELKKO ET AL., "An antibody-calmodulin fusion protein reveals a functional dependence between macromolecular isoelectric point and tumor targeting performance," Int. J. Radiation Oncology Biol. Phys., 2002, pages 1485-1490, vol. 54, no. 5.	
C51	PATRIZIA CASTELLANI ET AL., "Differentiation between High- and Low-Grade Astrocytoma Using a Human Recombinant Antibody to the Extra Domain-B of Fibronectin," American Journal of Pathology, November 2002, 1695-1700, vol. 161, no. 5, American Society for Investigative Pathology.	
C52	M SANTIMARIA ET AL., "Immunoscintigraphic Detection of the ED-B Domain of Fibronectin, a Marker of Angiogenesis, in Patients with Cancer," Clinical Cancer Research, February 2003, pages 571-579, vol. 9.	
C53	J SCHEUERMANN ET AL., "Discovery and investigation of lead compounds as binders to the extra-domain B of the angiogenesis marker, fibronectin," Drug Development Research, 2003, pages 268-282, vol. 58.	
C54	HALIN ET AL., "Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor α ," Cancer Research, 15 June 2003, pages 3202-3210, vol. 63.	
C55	L BORSI ET AL., "Selective targeted delivery of TNF α to tumor blood vessels," Blood First Edition Paper, prepublished online 21 August 2003, American Society of Hematology, DOI 10.1182/blood-2003-04-1039.	
C56	M NICOLO ET AL., "Expression of Extradomain-B-containing Fibronectin in Subretinal Choroidal Neovascular Membranes," 2003, Elsevier Science Inc.	
C57	F VITI ET AL., "Recombinant antibodies for the selective targeting of tumor neovasculature," Current Opinion in Drug Discovery & Development, 2002, pages 204-213, vol. 5, no. 2.	
C58	F VITI ET AL., "Phage display libraries as a source of tumour-targeting agents," Chimia, 2001, pages 206-211, vol. 55, ISSN 0009-4293, The Academic Polymer Scene in Switzerland.	
C59	D NERI ET AL., Edited by P. RIVA, "New Approaches to Tumour Targeting," Cancer Radioimmunotherapy: Present and Future, Nuclear Medicine Department, Hospital "M. Bufalini," Cesena, Italy, Harwood academic publishers.	
C60	M BIRCHLER ET AL., "Expression of the extra domain B of fibronectin, a marker of angiogenesis, in head and neck tumors," Laryngoscope, July 2003, pages 1231-1237, vol. 113.	
C61	J PETERS ET AL., "Fibronectin Isoform Distribution in the Mouse: II. Differential Distribution of the Alternatively Spliced EIIIB, EIIB, AND V Segments in the Adult Mouse," Cell Adhesion and Communication, 1996, pages 127-148, vol. 4, no. 2.	
C62	Chevalier, X., et al., "Increased expression of Ed-B-Containing fibronectin (an embryonic isoform of fibronectin) in human osteoarthritic cartilage," British Journal of Rheumatology, Vol. 35(5), pages 407-415, (abstract only)	

Examiner Signature	Date Considered
--------------------	-----------------

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Please type a plus sign (+) inside this box →

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/088,866	
			Filing Date	July 2, 2002	
			First Named Inventor	Ludger Dinkelborg et al.	
			Group Art Unit	1643	
			Examiner Name	Unknown	
Sheet	9	of	14	Attorney Docket Number	SCH-1869

C63	Chevalier, X., et al., "Presence of ED-A containing Fibronectin in human articular cartilage from patients with osteoarthritis and rheumatoid arthritis," Journal of Rheumatology, Vol. 23(6), pages 1022-1030, June 1996	
C64	Koukoulis, GK, et al., "Immunolocalization of cellular fibronectins in the normal liver, cirrhosis, and hepatocellular carcinoma," Ultrastructural pathology, Jan.-Feb. 1995, Vol. 19(1), pages 37-43	
C65	Moyano, JV, et al., "Fibronectin type III5 repeat contains a novel cell adhesion sequence, KLDAPT, which binds activated $\alpha 4 \beta 1$ and $\alpha 4 \beta 7$ integrins," Journal of Biological Chemistry, Oct. 3, 1997, Vol. 272(40), pages 24832-24836	
C66	Yu, J L, et al., "Fibronectin exposes different domains after adsorption to a heparinized and an unheparinized poly(vinyl chloride) surface," Biomaterial, March 1997, Vol. 18(56), pages 421-427	
C67	Borsi, L., et al., "Preparation of phage antibodies to the ED-A domain of human fibronectin," Exp. Cell Res., May 1, 1998, Vol. 240(2), p. 244-251	
C68	KACZMAREK, J ET AL., Int. J. Cancer, vol. 58, pages 11-16, 1994.	
C69	KIRKHAM, PM ET AL., J. Mol. Biol., 1999, pages 909-915, vol. 285.	
C70	MANABE, RI-ICHIROH ET AL., Journal of Cell Biology, vol. 139(1), pages 295-307, October 6, 1997.	
C71	MARDON, H J ET AL., Journal of Cell Science, vol. 104, pages 783-792, 1993.	
C72	MENZIN, A W et al. Cancer 1998, vol. 82, pages 152-158.	
C73	PAOLELLA, GIOVANNI E TAL, Nucleic acids research, vol. 16(8), pages 3545-3557, 1988.	
C74	STAFFA, A ET AL., The Journal of Biological Chemistry, 272(52), pages 33394-33401, December 1997.	
C75	VARTIO, T ET AL., "Differential expression of the ED sequence-containing form of cellular fibronectin in embryonic and adult human tissues," Journal of cell science, vol. 88, pages 419-430, 1987.	
C76	UEDA, YASUO ET AL., "Selective Distribution of Fibronectin to a Tumor-Cell Line," Cancer Letters, vol. 31, pages 261-265, 1986.	
C77	G MARIANI ET AL., "A pilot pharmacokinetic and immunoscintigraphic study with the technetium-99m-labeled monoclonal antibody BC-1 directed against oncofetal fibronectin in patients with brain tumors," Cancer, 15 Dec 1997, pages 2484-9, vol. 80, suppl. 12, ISSN: 0008-543X, Journal code: CLZ, abstract, USA.	
C78	CARNEMOLLA et al., Journal of Cell Biology, vol. 108, pages 1139-1148, 1989.	
C79	DARIO NERI et al., "High-affinity Antigen Binding by Chelating Recombinant Antibodies (CRAbs)," J. Mol. Biol. (1995) 246, 367-373	
C80	Ashley Publications Ltd., ISSN 1354-3776, "Antibodies to the ED-B domain of fibronectin, their constructs and uses," Exp. Opin. Ther. Patents (1998) 8(7):907-910	

Examiner Signature	Date Considered
--------------------	-----------------

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/088,866
				Filing Date	July 2, 2002
				First Named Inventor	Ludger Dinkelborg et al.
				Group Art Unit	1643
				Examiner Name	Unknown
Sheet	10	of	14	Attorney Docket Number	SCH-1869

	C81	FREDRIK NILSSON et al., "The use of phage display for the development of tumour targeting agents," Advanced Drug Delivery Reviews 43 (2000) 165-196	
	C82	EPSTEIN, Jay S., "FDA Regulation of HIV-Related Tests and Procedures," Aids Testing: A comprehensive Guide to Technical, Medical, Social, Legal, and Management Issues, Eds. Schochetman and George, pp. 52-61, Springer-Verlag, New York.	
	C83	KORVER et al., "Measurement of Primary In Vivo IgM- and IgG-Antibody Response to KLH in Humans: Implications of Pre-Immune IgM Binding in Antigen-Specific ELISA," Journal of Immunological Methods, 1984, pp. 241-251, vol. 74.	
	C84	WEIR, C. et al., "An Immunoglobulin G1 Monoclonal Antibody Highly Specific to the Wall of <i>Cryptosporidium</i> Oocysts," Clinical and Diagnostic Laboratory Immunology, Sept. 2000, p. 745-750, Vol. 7, No. 5.	
	C85	NOZAWA, Shiro, et al., "HMMC-1: A Humanized Monoclonal Antibody With Therapeutic Potential Against Müllerian Duct-Related Carcinomas," Clinical Cancer Research, October 15, 2004, pp. 7071-7078, vol. 10.	
	C86	23 slide, power-point of Dr. Zardi (February 2007).	
	C87	MATSUURA et al., "The oncofetal domain of fibronectin defined by monoclonal antibody FDC-6: Its presence in fibronectins from fetal and tumor tissues and its absence in those from normal adult tissues and plasma," Proc.Natl.Acad.Sci., vol. 82, pp 6517-6521, October 1985.	
	C88	MATSUURA et al., "An α -N-Acetylgalactosaminylation at the Threonine Residue of a Defined Peptide Sequence Creates the Oncofetal Peptide Epitope in Human Fibronectin," The Journal of Biological Chemistry, vol. 264, no. 18, pp 10472-10476, 1989.	
	C89	MATSUURA et al., "The Oncofetal Structure of Human Fibronectin Defined by Monoclonal Antibody FDC-6," The Journal of Biological Chemistry, vol. 263, No. 7, pp 3314-3322, 1988.	
	C90	ISEMURA et al., "Isolation and Characterization of Human Placenta Fibronectin," J.Biochem. 96, 163-169, 1984.	
	C91	BORSI L. et al.: "Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin," International Journal of Cancer, New York, NY, vol. 102, no. 1, November 1, 2002, pg. 75-85.	
	C92	LI ERQU et al.: "Mammalian cell expression of dimeric small immune proteins (SIP)," Protein Engineering, Oxford University, vol. 10, no. 6, 1997, pg. 731-736.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/088,866	
			Filing Date	July 2, 2002	
			First Named Inventor	Ludger Dinkelborg et al.	
			Group Art Unit	1643	
			Examiner Name	Unknown	
Sheet	11	of	14	Attorney Docket Number	SCH-1869

C93	ORLOVA ANNA et al.: "Comparative biodistribution of the radiohalogenated (Br, I and At) antibody A33. Implications for in vivo dosimetry," Cancer Biotherapy and Radiopharmaceuticals, vol. 17, no. 4, 2002, pg. 385-396.	
C94	ZALUTSKY MR et al.: "Astatine-211-labeled radiotherapeutics: An emerging approach to targeted alpha-particle radiotherapy," Current Pharmaceutical Design, Bentham Science Publ., vol. 6, September 2000, pg. 1433-1455.	
C95	RUDIHOFF, S., A.M. Giusti, W.D. Cook and M.D. Scharff, "Single amino acid substitution altering antigen-binding specificity," Proceedings of the National Academy of Sciences, 1982, vol. 79, pgs. 1979-1983.	
C96	MACCULLUM, R.M., A.C.R. Martin and J.M. Thornton, "Antibody-antigen interactions: contact analysis and binding site topography," Journal of Molecular Biology, 1996, vol. 262, pgs. 732-745.	
C97	PASCALIS, IWAHASHI, TAMURA, PADLAN, GONZALES, SANTOS, GIULANO, SCHUCK, SCHLOM, and KASHMIRI, "Grafting of 'abbreviated' complementarity-determining regions containing specific-determining residues essential for ligand contact to engineer a less immunogenic humanized monoclonal antibody," Journal of Immunology, 2002, vol. 169, pgs. 3076-3084.	
C98	CASSET, F., F. Roux, P. Mouchet, C. Bes, T. Chardes, C. Granier, J. Mani, M. Pugniere, D. Laune, B. Pau, M. Kaczorek, R. Lahana, and A. Rees, "A peptide mimetic of an anti-CD4 monoclonal antibody by rational design," Biochemical and Biophysical Research Communications, 2003, vol. 307, pgs. 198-205.	
C99	VAJDOS, F.F., C.W. Adams, T.N. Breece, L.G. Presta, A.M. Devos, and S.S. Sidhu, "Comprehensive functional maps of the antigen-binding site of an anti-ErbB2 antibody obtained with shotgun scanning mutagenesis," Journal of Molecular Biology, 2002, vol. 320, pgs. 415-428.	
C100	ARGRAVES et al., "Amino Acid Sequence of the Human Fibronectin Receptor," <i>Journal of Cell Biology</i> , Rockefeller University Press, New York, US, Vol. 105, 1987, pp. 1183-1190.	
C101	GARCIA-VELASCO et al., "Regulation of Monocyte Chemotactic Protein-1 Expression in Human Endometrial Stromal Cells by Integrin-Dependent Cell Adhesion," <i>Biology of Reproduction</i> , Vol. 61, No. 2, August 1999, pp. 548-552.	
C102	WAGNER et al., "Differentiation of Polymorphonuclear Neutrophils in Patients with Systemic Infections and Chronic Inflammatory Diseases: Evidence of Prolonged Life Span and de novo Synthesis of Fibronectin," <i>Journal of Molecular Medicine</i> , Vol. 78, No. 6, 2000, pp. 337-345.	
C103	CASTELLANI et al., "The Fibronectin Isoform Containing the ED-B Oncofetal Domain: A Marker of Angiogenesis," <i>International Journal of Cancer</i> , New York, NY, US, Vol. 59, No. 5, 12/01/1994, pp. 612-618.	

Examiner Signature	Date Considered
--------------------	-----------------

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Please type a plus sign (+) inside this box →

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/088,866
				Filing Date	July 2, 2002
				First Named Inventor	Ludger Dinkelborg et al.
				Group Art Unit	1643
				Examiner Name	Unknown
				Attorney Docket Number	SCH-1869
Sheet	12	of	14		

	C104	HASHIMOTO-UOSHIMA et al., "The Alternatively Spliced Domains EIIB and EIIA of Human Fibronectin Affect Cell Adhesion and Spreading," <i>Journal of Cell Science</i> , Vol. 110, No. 18, 1997, pp. 2271-2280.	
	C105	KERN A., Eble J., Golbik R., Kuhn K., "Interaction of Type IV Collagen with the Isolated Integrins Alpha 1 Beta 1 and Alpha 2 Beta 1", <i>Eur J. Biochem.</i> 215(a):151-159, 1993.	
	C106	NGO J.T., Marks J., Karplus M., "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox in the Protein Folding Problem," ch. 14, pp. 435-508, Birkhauser, 1994.	
	C107	KOGAN T.P., Revelle B.M., Tapp S., Scott D., Beck P.J., "A Single Amino Acid Residue can Determine the Ligand Specificity of E-Selectin", <i>J. Biol Chem.</i> 270(23:14047-55. 1995.	
	C108	TAKADA Y et al., "The Primary Structure of the VLA-2/Collagen Receptor Alpha 2 Subunit (Platelet GPIa): Homology to other Integrins and the Presence of a Possible Collagen-Binding Domain", <i>J. Cell Biol.</i> 109(1):397-407. 1989.	
	C109	BIRD RE, Hardman KD, Jacobson S, Kaufman BM, Lee SM, Lee T, Pope SH, Riordan GS, Whitlow M. Single-chain antigen-binding proteins. <i>Science.</i> 242(4877); 423-426, 1988.	
	C110	CHEN W, Culp LA. Adhesion mediated by fibronectin's alternatively spliced Edb (EIIB) and its neighboring type III repeats. <i>Exp. Cell Res.</i> 1996 Feb. 25, 223(1):9-19.	
	C111	BATISTA F D et al.; "The two membrane isoforms of human IgE assemble into functionally distinct B cell antigen receptors"; <i>THE JOURNAL OF EXPERIMENTAL MEDICINE.</i> , 1 Dec 1996, vol, 184, no. 6, pages 2197-2205	
	C112	CLACKSON et al., "Making antibody fragments using phage display libraries," <i>Nature</i> 352: 624-628, August 15, 1991.	
	C113	J. PETERS et al., "Expression of the alternatively spliced EIIB segment of fibronectin," <i>Cell Adhesion and Communication</i> , vol. 3 no. 1, 1995, USA, pgs. 67-89, XP002042097.	
	C114	ZANG, D. et al., "Antibody specific for extra domain B of fibronectin demonstrates elevated levels of both extra domain B (+) and B(-) fibronectin in osteoarthritic canine cartilage," <i>Matrix Biology</i> , vol. 14 no. 8, October 1995; Stuttgart, Germany, pgs. 623-633, XP002042098.	
	C115	DATABASE WPI Week 9017 Derwent Publications, Ltd., London, GB; AN 90-128252 XP002042103 & JP 02076598A (Fujita Gakuen et al.), 15 March 1990.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/088,866
Filing Date	July 2, 2002
First Named Inventor	Ludger Dinkelborg et al.
Group Art Unit	1643
Examiner Name	Unknown
Attorney Docket Number	SCH-1869

Sheet 13 of 14

C116	DATABASE WPI Week 9231 Derwent Publications, Ltd., London, GB; AN 92-253398 XP002042104 & JP 04169195A (Fujita Gakuen et al.), 17 June 1992.
C117	ZARDI, L. et al., "Transformed human cells produce a new fibronectin isoform by preferential alternative splicing of a previously unobserved exon," The Embo Journal, vol. 6 no. 8, August 1987, pgs. 2337-2342, XP002042100.
C118	CARNEMOLLA et al., "The inclusion of the type III repeat of ED-B in the fibronectin molecule generates conformational modifications that unmask a cryptic sequence," The Journal of Biological Chemistry, vol. 267 no. 34, 5 Dec. 1992, pgs. 24689-24692, XP002042101.
C119	CARNEMOLLA et al., "Phage antibodies with pan-species recognition of the oncofoetal angiogenesis marker fibronectin ED-B domain," International Journal of Cancer, vol. 68 no. 3, 4 Nov. 1996, pgs. 397-405, XP002042102.
C120	MAGNUSSON, M.K. et al., "Fibronectin: structure, assembly, and cardiovascular implications," Arteriosclerosis, Thrombosis, and Vascular Biology, Sep. 1998, vol.18 no. 9, pgs. 1363-1370.
C121	CASTELLANI, Patrizia et al., "Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin," American Journal of Pathology, Nov. 2002, vol. 161 no. 5, pgs. 1695-1700.
C122	Bauters et al., "Accumulation of fetal fibronectin mRNAs after balloon denudation of rabbit arteries." <i>Circulation</i> , vol. 92, pp. 904-911, 1995.
C123	Zhang et al., "Non-invasive imaging of atherosclerotic plaque macrophage in a rabbit model with F-18 FDG PET: a histopathological correlation." <i>BMC Nuclear Medicine</i> , vol. 25, pp. 1-7, 2006.
C124	Dinkelborg et al., "Molecular imaging of atherosclerosis using a technetium-99m-labeled endothelin derivative." <i>J Nucl Med.</i> , vol. 39, pp. 1819-1822, 1998.
C125	Demartis et al., "Selective targeting of tumour neovasculature by a radiohalogenated human antibody fragment specific for the ED-B domain of fibronectin." <i>European Journal of Nuclear Medicine</i> , vol. 28, pp. 534-539, 2001.
C126	Glukhova et al., "Expression of fibronectin variants in vascular and visceral smooth muscle cells in development." <i>Dev Biol.</i> , 1990, vol. 141(1) pp. 193-202, 1990.
C127	Berndorff et al., "Imaging of tumor angiogenesis using 99mTc-labeled human recombinant anti-ED-B fibronectin antibody fragments." <i>J Nucl Med.</i> 2006 Oct;47(10):1707-16.
C128	Marty et al., "Production of functionalized single-chain Fv antibody fragments binding to the ED-B domain of the B-isoform of fibronectin in <i>Pichia pastoris</i> ." <i>Protein Expr Purif.</i> 2001 Feb;21(1):156-64.
C129	George et al., "Radiometal labeling of recombinant proteins by a genetically engineered minimal chelation site: technetium-99m coordination by single-chain Fv antibody fusion proteins through a C-terminal cysteinyl peptide." <i>PNAS USA</i> 1995 Aug 29;92(18):8358-62.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/088,866
Filing Date	July 2, 2002
First Named Inventor	Ludger Dinkelborg et al.
Group Art Unit	1643
Examiner Name	Unknown
Attorney Docket Number	SCH-1869

Sheet 14 of 14

C130	COLMAN et al. (Research in Immunology 1994, 145:33-36).
C131	YANG, Wei-Ping et al., Journal of Molecular Biology 1995, vol. 254, pgs. 392-403, CDR Walking Mutagenesis for the affinity Maturation of a potent human Anti-HIV-1 antibody into the picomolar range.
C132	SCHIER, R. et al., Journal of Molecular Biology, 1996, vol. 263, pgs. 551-567.
C133	EPSTIEN, A.L. et al., "Identification of a Monoclonal Antibody, TV-1, Directed against the Basement Membrane of Tumor Vessels, and Its Use to Enhance Delivery of Macromolecules to Tumors after Conjugation with Interleukin 2," Cancer Research, vol. 55, 15 June 1995, pgs. 2673-2680.
C134	WILSON, Stephanie et al., "Simvastatin Preserves the Structure of Coronary Adventitial Vasa Vasorum in Experimental Hypercholesterolemia Independent of Lipid Lowering," Circulation, 29 Jan 2002, pgs. 415-418, XP002319108.
C135	FFRENCH-CONSTANT, Charles et al., "Alternative Splicing of fibronectin and spatially regulated in the chicken embryo," Development, vol. 106, 1989, pgs. 375-388.
C136	US Patent Application No. 10/507,178 filed September 10, 2004 and published March 16, 2006 under Publication No. US-2006-0057146-A1.
C137	US Patent Application No. 10/321,558 filed December 18, 2002 and published September 18, 2003 under Publication No. US-2003-0176663-A1.
C138	US Patent Application No. 11/637,810 filed December 13, 2006 and published August 16, 2007 under Publication No. US-2007-0189963-A1.
C139	US Patent Application No. 10/821,930 filed April 12, 2004 and published on June 22, 2006 under Publication No. US-2006-0133994-A1.
C140	US Patent Application No. 10/937,882 filed September 10, 2004 and published on April 7, 2005 under Publication No. US-2005-0074401-A1.
C141	US Patent Application No. 11/105,475 filed April 14, 2005 and published on October 6, 2005 under Publication No. US-2005-0221434-A1.
C142	US Patent Application No. 10/336,041 filed January 3, 2003 and published on January 1, 2004 under Publication No. US-2004-0001790-A1.
C143	US Patent Application No. 10/966,097 filed October 18, 2004 and published on May 26, 2005 under Publication No. US-2005-0112690-A1.
C144	US Patent Application No. 10/204,581 filed March 10, 2003 and published on January 22, 2004 under Publication No. US 2004-0013640 A1.

Examiner
Signature

Date
Considered

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.